Judith L Thijs1, Ian Strickland2, Carla A F M Bruijnzeel-Koomen3, Stefan Nierkens4, Barbara Giovannone1, Eszter Csomor2, Bret R Sellman5, Tomas Mustelin5, Matthew A Sleeman2, Marjolein S de Bruin-Weller3, Athula Herath2, Julia Drylewicz4, Richard D May2, DirkJan Hijnen6. 1. Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands. 2. MedImmune, Cambridge, United Kingdom. 3. Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands. 5. MedImmune, Gaithersburg, Md. 6. Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: dirkjanhijnen@gmail.com.
Abstract
BACKGROUND: Atopic dermatitis (AD) is a complex, chronic, inflammatory skin disease with a diverse clinical presentation. However, it is unclear whether this diversity exists at a biological level. OBJECTIVE: We sought to test the hypothesis that AD is heterogeneous at the biological level of individual inflammatory mediators. METHODS: Sera from 193 adult patients with moderate-to-severe AD (six area, six sign atopic dermatitis [SASSAD] score: geometric mean, 22.3 [95% CI, 21.3-23.3] and 39.1 [95% CI, 37.5-40.9], respectively) and 30 healthy control subjects without AD were analyzed for 147 serum mediators, total IgE levels, and 130 allergen-specific IgE levels. Population heterogeneity was assessed by using principal component analysis, followed by unsupervised k-means cluster analysis of the principal components. RESULTS: Patients with AD showed pronounced evidence of inflammation compared with healthy control subjects. Principal component analysis of data on sera from patients with AD revealed the presence of 4 potential clusters. Fifty-seven principal components described approximately 90% of the variance. Unsupervised k-means cluster analysis of the 57 largest principal components delivered 4 distinct clusters of patients with AD. Cluster 1 had high SASSAD scores and body surface areas with the highest levels of pulmonary and activation-regulated chemokine, tissue inhibitor of metalloproteinases 1, and soluble CD14. Cluster 2 had low SASSAD scores with the lowest levels of IFN-α, tissue inhibitor of metalloproteinases 1, and vascular endothelial growth factor. Cluster 3 had high SASSAD scores with the lowest levels of IFN-β, IL-1, and epithelial cytokines. Cluster 4 had low SASSAD scores but the highest levels of the inflammatory markers IL-1, IL-4, IL-13, and thymic stromal lymphopoietin. CONCLUSION: AD is a heterogeneous disease both clinically and biologically. Four distinct clusters of patients with AD have been identified that could represent endotypes with unique biological mechanisms. Elucidation of these endotypes warrants further investigation and will require future intervention trials with specific agents, such as biologics.
BACKGROUND:Atopic dermatitis (AD) is a complex, chronic, inflammatory skin disease with a diverse clinical presentation. However, it is unclear whether this diversity exists at a biological level. OBJECTIVE: We sought to test the hypothesis that AD is heterogeneous at the biological level of individual inflammatory mediators. METHODS: Sera from 193 adult patients with moderate-to-severe AD (six area, six sign atopic dermatitis [SASSAD] score: geometric mean, 22.3 [95% CI, 21.3-23.3] and 39.1 [95% CI, 37.5-40.9], respectively) and 30 healthy control subjects without AD were analyzed for 147 serum mediators, total IgE levels, and 130 allergen-specific IgE levels. Population heterogeneity was assessed by using principal component analysis, followed by unsupervised k-means cluster analysis of the principal components. RESULTS:Patients with AD showed pronounced evidence of inflammation compared with healthy control subjects. Principal component analysis of data on sera from patients with AD revealed the presence of 4 potential clusters. Fifty-seven principal components described approximately 90% of the variance. Unsupervised k-means cluster analysis of the 57 largest principal components delivered 4 distinct clusters of patients with AD. Cluster 1 had high SASSAD scores and body surface areas with the highest levels of pulmonary and activation-regulated chemokine, tissue inhibitor of metalloproteinases 1, and soluble CD14. Cluster 2 had low SASSAD scores with the lowest levels of IFN-α, tissue inhibitor of metalloproteinases 1, and vascular endothelial growth factor. Cluster 3 had high SASSAD scores with the lowest levels of IFN-β, IL-1, and epithelial cytokines. Cluster 4 had low SASSAD scores but the highest levels of the inflammatory markers IL-1, IL-4, IL-13, and thymic stromal lymphopoietin. CONCLUSION:AD is a heterogeneous disease both clinically and biologically. Four distinct clusters of patients with AD have been identified that could represent endotypes with unique biological mechanisms. Elucidation of these endotypes warrants further investigation and will require future intervention trials with specific agents, such as biologics.
Authors: Lieneke F M Ariëns; Daphne S Bakker; Jorien van der Schaft; Floor M Garritsen; Judith L Thijs; Marjolein S de Bruin-Weller Journal: Ther Adv Chronic Dis Date: 2018-05-11 Impact factor: 5.091
Authors: Jacob P Thyssen; Teresa Berents; Maria Bradley; Mette Deleuran; Øystein Grimstad; Laura Korhonen; Tor Langeland; Tore Särnhult; Simon Francis Thomsen; Turid Thune; Carl-Fredrik Wahlgren; Christian Vestergaard; Laura B Kobyletzki; Anita Remitz Journal: Acta Derm Venereol Date: 2020-01-07 Impact factor: 3.875
Authors: Micah Belzberg; Martin Prince Alphonse; Isabelle Brown; Kyle A Williams; Raveena Khanna; Byron Ho; Shannon Wongvibulsin; Thomas Pritchard; Youkyung Sophie Roh; Nishadh Sutaria; Justin Choi; Jaroslaw Jedrych; Andrew D Johnston; Kakali Sarkar; Chirag Vasavda; Jimmy Meixiong; Carly Dillen; Kent Bondesgaard; John F Paolini; Wei Chen; David Corcoran; Nicolas Devos; Madan M Kwatra; Anna L Chien; Nathan K Archer; Luis A Garza; Xinzhong Dong; Sewon Kang; Shawn G Kwatra Journal: J Invest Dermatol Date: 2021-03-23 Impact factor: 7.590
Authors: Tesfaye B Mersha; Yashira Afanador; Elisabet Johansson; Steven P Proper; Jonathan A Bernstein; Marc E Rothenberg; Gurjit K Khurana Hershey Journal: Clin Rev Allergy Immunol Date: 2021-04 Impact factor: 8.667
Authors: Lam C Tsoi; Elke Rodriguez; Frauke Degenhardt; Hansjörg Baurecht; Ulrike Wehkamp; Natalie Volks; Silke Szymczak; William R Swindell; Mrinal K Sarkar; Kalpana Raja; Shuai Shao; Matthew Patrick; Yilin Gao; Ranjitha Uppala; Bethany E Perez White; Spiro Getsios; Paul W Harms; Emanual Maverakis; James T Elder; Andre Franke; Johann E Gudjonsson; Stephan Weidinger Journal: J Invest Dermatol Date: 2019-01-11 Impact factor: 7.590
Authors: Jianghui Meng; Yanqing Li; Michael J M Fischer; Martin Steinhoff; Weiwei Chen; Jiafu Wang Journal: Front Immunol Date: 2021-06-30 Impact factor: 7.561